05-321MG
Anti-Phosphotyrosine Antibody, clone 4G10®
clone 4G10®, Upstate®, from mouse
Synonym(s):
Clone 4G10 Anti-Phosphotyrosine, Phosphotyrosine Detection Antibody
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
4G10®, monoclonal
Technique(s):
immunoprecipitation (IP): suitable, western blot: suitable
Application:
IP, WB
Citations:
6
biological source
mouse
Quality Level
antibody form
purified from hybridoma cell culture
antibody product type
primary antibodies
clone
4G10®, monoclonal
species reactivity (predicted by homology)
all
manufacturer/tradename
Upstate®
technique(s)
immunoprecipitation (IP): suitable, western blot: suitable
isotype
IgG2bκ
shipped in
wet ice
target post-translational modification
phosphorylation (pTyr)
General description
Dependent upon the molecular weight of the tyrosine phosphorylated protein being detected.
Application
Anti-Phosphotyrosine Antibody, clone 4G10 detects level of Phosphotyrosine & has been published & validated for use in IP & WB.
Physical form
Format: Purified
Purified mouse monoclonal IgG2bκ in buffer containing PBS, pH 7.4. Liquid at 2-8ºC.
IgG2bκ mouse monoclonal antibody produced in vitro by mouse-mouse hybridoma 4G10 (FOX-NY [NS-1 derivative] myeloma x spleen cells).
IgG2bκ mouse monoclonal antibody produced in vitro by mouse-mouse hybridoma 4G10 (FOX-NY [NS-1 derivative] myeloma x spleen cells).
Analysis Note
Control
Positive Antigen Control: Catalog #12-302, EGF-stimulated A431 cell lysate. Add 2.5µL of 2-mercaptoethanol/100µL of lysate and boil for 5 minutes to reduce the preparation. Load 20µg of reduced lysate per lane for minigels.
Positive Antigen Control: Catalog #12-302, EGF-stimulated A431 cell lysate. Add 2.5µL of 2-mercaptoethanol/100µL of lysate and boil for 5 minutes to reduce the preparation. Load 20µg of reduced lysate per lane for minigels.
Routinely evaluated on EGF-treated human A431 carcinoma cells.
Western Blot Analysis:
0.5-2 μg/mL of this lot detected tyrosine-phosphorylated proteins in a modified RIPA lysate from EGF-treated human A431 carcinoma cells (Cohen, B., 1990; Druker, B. J., 1989; Kanakura, Y., 1991).
Western Blot Analysis:
0.5-2 μg/mL of this lot detected tyrosine-phosphorylated proteins in a modified RIPA lysate from EGF-treated human A431 carcinoma cells (Cohen, B., 1990; Druker, B. J., 1989; Kanakura, Y., 1991).
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
4G10 is a registered trademark of Upstate Group, Inc.
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Anti-Phosphotyrosine Antibody, clone 4G10®
— or —
Try our Product Selector Tool to narrow your options
Storage Class
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xin A Zhang et al.
The Journal of biological chemistry, 278(29), 27319-27328 (2003-05-10)
KAI1/CD82 protein is a member of the tetraspanin superfamily and has been rediscovered as a cancer metastasis suppressor. The mechanism of KAI1/CD82-mediated suppression of cancer metastasis remains to be established. In this study, we found that migration of the metastatic
Zhi Liu et al.
The Journal of biological chemistry, 290(12), 7535-7562 (2015-01-15)
Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for preclinical and clinical testing is a challenging task. Here, we describe a new strategy for making monovalent bispecific heterodimeric IgG antibodies in mammalian cells. We applied an
Hoang Thanh Chi et al.
Biomedical reports, 19(1), 47-47 (2023-06-29)
ETS variant transcription factor 6 (ETV6)-neurotrophic receptor tyrosine kinase 3 (NTRK3) (EN) fusions are typically found in rare diseases, such as primary renal fibrosarcoma (only six cases have been reported), secretory carcinoma of the breast and salivary gland (1 case)